Lead StrategistCiVi Biopharma A/S
Company details
- CVR number
- 38027794
- Status
- inaktiv
- Legal form
- Public limited company (A/S)
- Founded
- 20 September 2016
This company has advertising protection (reklamebeskyttelse) in the CVR register and must not be contacted for marketing. No contact details are shown.
Find similar companies in the same industry and build a lead list right inside your AI.
Key figures
The latest 3 financial years from the annual reports. Amounts in Danish kroner (DKK).
| Financial year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Gross profit | DKK 611k | DKK 3.5m | DKK 3.5m |
| Net profit | −DKK 1.4m | −DKK 1.9m | DKK 326k |
| Equity | DKK 78k | DKK 1.5m | DKK 3.4m |
| Employees (avg.) | 1 | 1 | 1 |
Track the trend via the API.REST API (OpenAPI)
Get all 5 years of financials right inside Claude or ChatGPT via MCP.
Similar companies
Active companies in the same industry and municipality or close in size.
- Lockto ApS
9530 Støvring
1 employee · gross profit DKK 628k (2025)
- Acculution ApS
2650 Hvidovre
1 employee · gross profit DKK 614k (2025)
- Bytesnbio ApS
8410 Rønde
1 employee · gross profit DKK 614k (2025)
- Ekoplan APS
9500 Hobro
1 employee · gross profit DKK 613k (2025)
- COPAC A/S
2860 Søborg
1 employee · gross profit DKK 593k (2025)
- FM UDVIKLING ApS
4100 Ringsted
1 employee · gross profit DKK 590k (2025)
- InnoTech Vision ApS
8830 Tjele
1 employee · gross profit DKK 573k (2025)
- Wilkmann Dynamics ApS
4320 Lejre
1 employee · gross profit DKK 558k (2025)
See all:Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (1,362)
Full financials and history
Lead Strategist is free during the beta with 20,000 credits a month. Get every figure for this company right inside your AI or via the API.
- All 5 financial years in the database
- Balance sheet: assets, liabilities, provisions and cash
- EBIT, gross profit and reporting class
- Auditor and audit firm
Free beta · 20,000 credits a month · no card
By creating an account you accept the terms on behalf of your business.